Senate Dems boycott vote on Price as HHS Secretary

Nicholas Leider | | Health Exec | Policy & Regulations

The Senate finance committee scheduled a hearing for Tuesday morning to vote on the confirmation of Tom Price, MD, as the next HHS Secretary. Democrats, however, did not show up.

The boycott may be related to President Donald Trump's firing of Acting Attorney General Sally Yates for refusing to defend his executive order banning certain immigrants and refugees. But the no-show may also have to do with recent accusations that Price, a member of the House of Representatives from Georgia, may have received a privileged offer to buy biomedical stock, something that ran contrary to his testimony at confirmation hearings, according the the Wall Street Journal.

Democrats also boycotted the scheduled vote for Steve Mnuchin, Trump's choice for Secretary of the Treasury. Senator Orrin Hatch, R-Utah, the Finance Committee Chairman, dismissed the no-show as political theater.

“They ought to stop posturing and acting like idiots,” he said.

""
Nicholas Leider, Managing Editor

Nicholas joined TriMed in 2016 as the managing editor of the Chicago office. After receiving his master’s from Roosevelt University, he worked in various writing/editing roles for magazines ranging in topic from billiards to metallurgy. Currently on Chicago’s north side, Nicholas keeps busy by running, reading and talking to his two cats.

Related Content

Papers discussing ‘gender’ have been restored to government website
AMA agrees to help after initial request for an independent cardiovascular board was denied
AMA president warns prior authorization hurting patients, driving burnout and practice closures
Veterans Affairs denies it discriminates based on politics, marital status
Dexcom recalls more than 2 million CGM receivers over safety issues—dozens of adverse events reported
Ivenix infusion kits recalled by FDA due to serious manufacturing defect

Around the web

Cardiovascular Business
AMA agrees to help after initial request for an independent cardiovascular board was denied

After their proposal for a new American Board of Cardiovascular Medicine was shot down earlier this year, cardiology groups have asked the AMA for some support. "We feel like it's time for us to blaze our own path," one specialist explained. 

Cardiovascular Business
Eli Lilly to acquire gene-editing specialists focused on CVD for up to $1.3B

The company has agreed to acquire Verve Therapeutics for an upfront payment of approximately $1 billion. The total could increase significantly, however, if certain milestones are met. One of Verve's biggest gene therapies has already received the FDA's fast track designation.

Cardiovascular Business
AMA House of Delegates helps cardiology groups influence healthcare policies

American College of Cardiology Board of Governors Chair David E. Winchester, MD, MS, examines the many benefits of working with the American Medical Association House of Delegates to bring about significant change.